#### **TRIUMF TR13**

Date form last updated: 2016 May 29

Completed by: David Prevost

## 1. Cyclotron Facility – Contact info

Institute (name/address):	TRIUMF 4004 Wesbrook Mall Vancouver, BC V6T 2A3 Canada
Institution URL:	http://www.triumf.ca/
Person in charge (name/ph#/email):	Dr. Paul Schaffer
Position/title:	Associate Lab Director - Life Sciences Division
Cyclotron manager/engineer (name/ph#/email)	David Prevost
	604-222-1047 ext 6552
	dprevost@triumf.ca
QA manager (name/ph#/email)	
QC manager	
Other senior staff (titles/name/ph#/email):	

## 2. Cyclotron characteristics

Cyclotron manufacturer/model	EBCO TR13
Cyclotron installation date (Year):	1994
Dual beam?	□No ⊠Yes
Any upgrades?	⊠No □Yes, Describe:
Particles:	⊠¹H □²H □³He □⁴He
Particle energy, or range (MeV):	13_ <sup>1</sup> H <sup>2</sup> H <sup>3</sup> He <sup>4</sup> He
Max particle current (uA):	100_ <sup>1</sup> H <sup>2</sup> H <sup>3</sup> He <sup>4</sup> He
Typical particle current (uA):	25_ <sup>1</sup> H <sup>2</sup> H <sup>3</sup> He <sup>4</sup> He

## 3. Cyclotron Operation $\square$ Prefer not to answer

Planned operating days per week:	□1	□2	□3	□4	⊠5	□6	□7
Number of planned maintenance days/month:	2						
Number of planned shutdown weeks per year:	0						
Total operating hours (h)/week:	25						
h/week for radionuclide production:	15						
h/week for research:	4						
h/week for maintenance:	4			•		•	
h/week for applications:	2						

4.	Is the c	cyclotron	used to	produce	☐ Prefer	not to	answer
----	----------	-----------	---------	---------	----------	--------	--------

Calibration sources? (specify which & quantity)	⊠No ⊠Yes
Mossbauer sources? (specify which & quantity)	⊠No □Yes
X-ray sources? (specify which & quantity)	⊠No □Yes
Intense neutron beam? (specify average $E_n = ?$ )	⊠No □Yes

# 5. Application questions $\square$ Prefer not to answer

Are pre-clinical studies using cyclotron radiopharmaceuticals carried out on-site?	⊠No □Yes (if available, types of radiotracers and name(s) and email(s) of PIs):
Are clinical studies using cyclotron radiopharmaceuticals carried out on-site?	⊠No ☐Yes (if available, types of radiotracers and name(s) and email(s) of PIs):
Are cyclotron radionuclides/labelled compounds used or planned to be used for agricultural applications such as plant biochemistry/research?	□No ⊠Yes (if available, types of radiotracers and name(s) and email(s) of PIs):
Is the cyclotron used for nuclear reaction cross-section measurements?	☐No ☐Yes (if available, name(s) and email(s) of PIs):
Is the cyclotron used for targetry development?	☐No ☐Yes (if available, types of isotopes, and name(s) and email(s) of PIs):
Is the cyclotron used for materials science?	☐No ☐Yes (if available, name(s) and email(s) of PIs):
Is the cyclotron used for radiography?	☐No ☐Yes (if available, name(s) and email(s) of PIs):
Is the cyclotron used for radiobiology?	⊠No □Yes (if available, name(s) and email(s) of PIs):
Is the cyclotron used for physics research?	⊠No □Yes (if available, name(s) and email(s) of PIs):
Is the cyclotron used for activation analysis?	⊠No □Yes (if available, name(s) and email(s) of PIs):
Is the cyclotron used for proton therapy?	⊠No □Yes (if available, name(s) and email(s) of PIs):
Is the cyclotron used for neutron therapy?	⊠No □Yes (if available, name(s) and email(s) of PIs):
Other (specify)	☐No ☐Yes (if available, name(s) and email(s) of PIs):

Types of imaging equipment  $\square$  N/A,  $\square$  Prefer not to answer

Single photon (specify if gamma camera, SPECT,	511 KeV Coincidence, Gamma camera, Single
or SPECT-CT):	Photon Tomography (SPET)
Number of clinical scanners:	
Number of pre-clinical scanners:	
Number of plant biochemistry scanners:	
PET (specify if PET, PET/CT, or PET/MR):	PET: 3
Number of clinical scanners:	
Number of pre-clinical scanners:	
Number of plant biochemistry scanners:	

6. Do you supply radionuclide(s), radiotracer(s), or radiopharmaceutical(s) to other institutions? (⊠No/□Yes/□ Prefer not to answer). If yes, and if available, please provide the name of product, institution, and supply frequency:

Product	Institution	Frequency (annual)		
Raclopride (RAC)	UBC	50		
Dihydrotetrabenazine (DTBZ)	UBC	40		
Methyl Phenidate (MP)	UBC	18		
Pittsburgh Compound B (PIB)	UBC	9		
Methylpiperidin-4-yl Propionate (PMP)	UBC	15		
Methylreboxetine (MRB)	UBC	13		
Yohimbine	UBC	13		
3-amino-4-(2-	UBC	13		
dimethylaminomethylphenylsulfanyl)-				
benzonitrile (DASB)				
Peripheral Benzodiazapine Receptor	UBC	64		
(PBR28)				
(2-((1E,3E)-4-(6-((11)C-	UBC	17		
methylamino)pyridin-3-yl)buta-1,3-				
dienyl) benzo[d]thiazol-6-ol) (PBB3)				
Fluorodopa (FDOPA)	UBC/BCCA	31		
2-nitroimidazole (EF5)	BCCA	10		

#### 7. Cyclotron/radionuclide/radiochemistry/radiopharmacy training

Is the cyclotron used for education and training in nuclear sciences, health physics, etc?	⊠No	☐Yes (if available, name(s) and email(s) of PIs):
Does your institute participate in trainee exchange (for production):	⊠No	☐Yes (if available, name(s) and email(s) of PIs):
Does your institute participate in trainee exchange (for research):	⊠No	☐Yes (if available, name(s) and email(s) of PIs):
Does your institute accept IAEA research fellows for training/experience:	⊠No	☐Yes (if available, name(s) and email(s) of PIs):
Other training opportunities (specify):	⊠No	☐Yes (if available, name(s) and email(s) of PIs):

8. Radionuclide production -	$^{-18}$ F( $F^{\scriptscriptstyleT}$ ) $oxtimes$ N/A, $oxtimes$ Prefer not to answer
Reaction	$\boxtimes^{18} O(p,n)^{18} F;  \Box^{16} O(^{3} He,p)^{18} F;  \Box^{20} Ne(d,\gamma)^{18} F;  \Box^{16} O(\alpha,d)^{18} F$
Typical current (μΑ):	20
Typical energy (MeV):	13
Typical yield (GBq):	
Typical target pressure (psi):	400
Is target He cooled?	□No ⊠Yes
Typical beam time (min):	45
Typical Y <sub>sat</sub> if known (GBq/μA)	
% Isotopic enrichment <sup>18</sup> O	>95
<sup>18</sup> O supplier(s)	
Target volume [ <sup>18</sup> O]H <sub>2</sub> O (mL)	0.5
Usage per year [ <sup>18</sup> O]H <sub>2</sub> O (mL)	50
Do you recycle [ <sup>18</sup> O]H <sub>2</sub> O?	□No ⊠Yes (if "yes", □in-house ⊠return to supplier)
- ,	ino zires (ii yes , ziii ilouse ziretuii to supplier,
9 Radionuclide production -	$-^{11}$ C ([ $^{11}$ C]CH <sub>4</sub> ) $\boxtimes$ N/A, $\square$ Prefer not to answer
3. Radionacinae production	C ([ C]CH4/ 🖾 N/A, 🗀 Freier not to answer
Typical current (μA):	20
Typical energy (MeV):	13
Typical yield (GBq):	
Typical target pressure (psi):	400
Typical beam time (min):	30
Typical Y <sub>sat</sub> if known (GBq/μA):	
Gas mixture:	10% H <sub>2</sub> , 90% N <sub>2</sub>
Target volume:	~18mL
[ <sup>11</sup> C]CH <sub>3</sub> I production ASU model:	
Typical yield (GBq):	1.1
Typical yield (%, d.c.):	
	11- (11-2-2-)
10. Radionuclide production -	$-^{11}$ C ([ $^{11}$ C]CO $_2$ ) $\boxtimes$ N/A, $\square$ Prefer not to answer
Typical current (μΑ):	25
Typical energy (MeV):	13
Typical yield (GBq):	
Typical target pressure (psi):	440
Typical beam time (min):	45
Typical Y <sub>sat</sub> if known (GBq/μA):	
Gas mixture:	
Target volume:	~18mL
[ <sup>11</sup> C]CH <sub>3</sub> I production ASU model:	
Typical yield (GBq):	1.6
Typical yield (%, d.c.):	1

11.	Other	radionu	ıclides	produced	$\square$ N	/A, ⊠	Prefer	not to	answer
-----	-------	---------	---------	----------	-------------	-------	--------	--------	--------

Product	Yield on batch	Irradiation parameters	Typical target mass/material	Extraction method	Used on site?	Distribution/ sales?
	(GBq)	(MeV/μA/min)				
<sup>13</sup> N					□No □Yes	□No □Yes
<sup>15</sup> O					□No □Yes	□No □Yes
<sup>18</sup> F-F <sub>2</sub>					□No □Yes	□No □Yes
<sup>44</sup> Sc					□No □Yes	□No □Yes
<sup>64</sup> Cu					□No □Yes	□No □Yes
<sup>67</sup> Ga					□No □Yes	□No □Yes
<sup>86</sup> Y					□No □Yes	□No □Yes
<sup>89</sup> Zr					□No □Yes	□No □Yes
<sup>94m</sup> Tc					□No □Yes	□No □Yes
<sup>99m</sup> Tc					□No □Yes	□No □Yes
<sup>103</sup> Pd					□No □Yes	□No □Yes
<sup>111</sup> In					□No □Yes	□No □Yes
<sup>123</sup>					□No □Yes	□No □Yes
<sup>124</sup>					□No □Yes	□No □Yes
<sup>201</sup> TI					□No □Yes	□No □Yes
<sup>211</sup> At					□No □Yes	□No □Yes
Other:					□No □Yes	□No □Yes
					□No □Yes	□No □Yes
					□No □Yes	□No □Yes
					□No □Yes	□No □Yes
_					□No □Yes	□No □Yes

# 12. Radiopharmaceutical production – $^{18}$ F(FDG) $\square$ N/A, $\square$ Prefer not to answer

~1
□No ⊠Yes
⊠No □Yes
□pre/post dose-cal; or □indirectly via ASU
□ N/A
□pre/post dose-cal; or □indirectly via ASU
□ N/A
□pre/post dose-cal; or □indirectly via ASU

·	Other Products (please copy table for as many products as
desired) $\square$ N/A, $\boxtimes$ Prefer not to ar	nswer
Product:	
Production frequency (batches/week)	
Stage:	□R&D □Pre-clinical □Clinical
Used on site	□No □Yes
Distribution/sales	□No □Yes
ASU model	
Typical yield (GBq):	
Typical yield (%, decay corrected):	$\square$ pre/post dose-cal; or $\square$ indirectly via ASU
ASU model	□ N/A
Typical yield (GBq):	
Typical yield (%, decay corrected):	□pre/post dose-cal; or □indirectly via ASU
□ N/A, ⊠ Prefer not to answer	
Product: Application:	
15. Additional comments: ⊠ N/A	